BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 21590689)

  • 1. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
    Reardon DA; Desjardins A; Peters KB; Vredenburgh JJ; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Coan A; Threatt S; Friedman AH; Friedman HS
    Cancer; 2011 Dec; 117(23):5351-8. PubMed ID: 21590689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
    Reardon DA; Desjardins A; Peters KB; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Bulusu A; Threatt S; Friedman AH; Vredenburgh JJ; Friedman HS
    J Neurooncol; 2012 Mar; 107(1):155-64. PubMed ID: 21986722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
    Hasselbalch B; Lassen U; Hansen S; Holmberg M; Sørensen M; Kosteljanetz M; Broholm H; Stockhausen MT; Poulsen HS
    Neuro Oncol; 2010 May; 12(5):508-16. PubMed ID: 20406901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
    Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
    Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
    Zhang G; Huang S; Wang Z
    J Clin Neurosci; 2012 Dec; 19(12):1636-40. PubMed ID: 23047061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
    Kreisl TN; Kim L; Moore K; Duic P; Royce C; Stroud I; Garren N; Mackey M; Butman JA; Camphausen K; Park J; Albert PS; Fine HA
    J Clin Oncol; 2009 Feb; 27(5):740-5. PubMed ID: 19114704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
    Field KM; Simes J; Nowak AK; Cher L; Wheeler H; Hovey EJ; Brown CS; Barnes EH; Sawkins K; Livingstone A; Freilich R; Phal PM; Fitt G; ; Rosenthal MA
    Neuro Oncol; 2015 Nov; 17(11):1504-13. PubMed ID: 26130744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
    J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas.
    Kaloshi G; Diamandi P; Cakani B; Brace G; Rroji A; Petrela M
    Tumori; 2015; 101(1):41-5. PubMed ID: 25702676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
    Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
    Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
    Friedman HS; Prados MD; Wen PY; Mikkelsen T; Schiff D; Abrey LE; Yung WK; Paleologos N; Nicholas MK; Jensen R; Vredenburgh J; Huang J; Zheng M; Cloughesy T
    J Clin Oncol; 2009 Oct; 27(28):4733-40. PubMed ID: 19720927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma.
    Arakawa Y; Mizowaki T; Murata D; Fujimoto K; Kikuchi T; Kunieda T; Takahashi JC; Takagi Y; Miyamoto S
    Neurol Med Chir (Tokyo); 2013; 53(11):779-85. PubMed ID: 24140770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
    Vredenburgh JJ; Desjardins A; Herndon JE; Marcello J; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Wagner M; Bailey L; Bigner DD; Friedman AH; Friedman HS
    J Clin Oncol; 2007 Oct; 25(30):4722-9. PubMed ID: 17947719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.
    Gállego Pérez-Larraya J; Lahutte M; Petrirena G; Reyes-Botero G; González-Aguilar A; Houillier C; Guillevin R; Sanson M; Hoang-Xuan K; Delattre JY
    Neuro Oncol; 2012 May; 14(5):667-73. PubMed ID: 22492961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective observational analysis to evaluate the off-label use of bevacizumab alone or with irinotecan in recurrent glioblastoma.
    Cecchi M; Vaiani M; Ceroti M; Banfi R
    Int J Clin Pharm; 2013 Jun; 35(3):483-7. PubMed ID: 23536107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of carboplatin and weekly irinotecan combination chemotherapy in recurrent ovarian cancer: a Kansai clinical oncology group study (KCOG0330).
    Tsubamoto H; Kawaguchi R; Ito K; Shiozaki T; Takeuchi S; Itani Y; Arakawa A; Tabata T; Toyoda S
    Anticancer Res; 2013 Mar; 33(3):1073-9. PubMed ID: 23482784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab and daily temozolomide for recurrent glioblastoma.
    Desjardins A; Reardon DA; Coan A; Marcello J; Herndon JE; Bailey L; Peters KB; Friedman HS; Vredenburgh JJ
    Cancer; 2012 Mar; 118(5):1302-12. PubMed ID: 21792866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
    Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
    Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
    Vredenburgh JJ; Desjardins A; Herndon JE; Dowell JM; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Wagner M; Bigner DD; Friedman AH; Friedman HS
    Clin Cancer Res; 2007 Feb; 13(4):1253-9. PubMed ID: 17317837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.